MEDIAN Technologies, START expand working relationship

MEDIAN Technologies has announced it is expanding its relationship with START, a Phase 1 medical oncology company, to provide its services to more START locations.

MEDIAN has already been providing services to the START facility in San Antonio, Texas, for the last two years. Now that collaboration, which includes access to MEDIAN’s Lesion Management Solution (LMS), will expand to START’s centers in Grand Rapids, Mich., and Madrid, Spain.

“We are very proud and enthusiastic about this expansion with START,”  Fredrik Brag, MEDIAN Technologies chairman and CEO, said in a prepared statement. “START’s reputation for excellence and innovation through technology make it an ideal partner for us. We believe that our LMS application provides immense value for better assessing oncology patients’ response to therapy in clinical trials. The addition of our LMS application to START’s current capabilities will continue to bring tremendous combined value to the Phase I setting. Having accurate quantitative information from images helps sponsors make the right decisions regarding the pursuit of research on a given molecule, which ultimately benefits patients.”

“START is proud to expand MEDIAN’s LMS application to more sites,” Anthony Tolcher, MD, START director of clinical research, said in the same statement. “This innovative imaging technology nicely complements our web-based real-time delivery of clinical trial data and will assist our clinical trial sponsors to objectively verify responses in real-time and, we believe, help many of them identify opportunities for breakthrough designation. Imaging has a growing significance in phase I oncology trials, so expanding LMS to our arsenal of innovative tools will provide sponsors with valuable data that will support not only the early phase decision making, but also help lay the groundwork for follow-on, late phase trials.”